For the first half, revenue was 350.4 hundred million yen, operating income was 115.2 hundred million yen, and net income attributable to owners of parent was 119.5 hundred million yen. Full-year forecasts were also revised upward, incorporating the IntraBio acquisition to continue growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4507-20261029-04.pdf","jir_short_summary":"For the first half, revenue was 350.4 hundred million yen, operating income was 115.2 hundred million yen, and net income attributable to owners of parent was 119.5 hundred million yen. Full-year forecasts were also revised upward, incorporating the IntraBio acquisition to continue growth.","jir_summary":"### Overview of Results\nIn fiscal 2026 Q2, Shionogi & Co., Ltd. achieved revenue of 350.4 hundred million yen and operating income of 115.2 hundred million yen. Profitability increased significantly year-over-year, and EBITDA expanded to 174.6 hundred million yen. Strong royalty income, contributions from overseas subsidiaries and exports, and contributions from Torii Pharmaceutical-related products were key drivers. Full-year forecasts for FY2026 were also revised, assuming completion of the IntraBio acquisition.\n\n### Outlook and Investment Considerations\nFull-year forecasts for FY2026 were revised upward. The outlook incorporates the launch of AQNEURSA following the IntraBio acquisition, recognition of intangible asset amortization, and strategic R&D investments, and expects continued revenue and profit growth. The financial policy also mentions a stance toward increasing the interim dividend and opportunities for share buybacks.","jir_financial_highlights":"Revenue: 3,504 (Year-over-Year: +103.1%)\nOperating Income: 1,152 (Year-over-Year: +120.0%)\nNet Income Attributable to Owners of Parent (Interim): 1,195 (Year-over-Year: +110.7%)\nEBITDA: 1,746 (Year-over-Year: +103.4%)\nFull-year Revenue Forecast (FY2026): 7,200 (Revision Amount: +200)","jir_category":"","jir_hashtags":"#Shionogi, #FinancialResults, #FinancialPolicy","jir_key_figures":"Revenue: 3,504 (Year-over-Year +103.1%)\nOperating Income: 1,152 (Year-over-Year +120.0%)\nEBITDA: 1,746 (Year-over-Year +103.4%)","jir_meta_title":"Shionogi & Co., Ltd. FY2026 Q2 Financial Results\uff5cRevenue 350.4 hundred million yen, Operating Income 115.2 hundred million yen","jir_meta_description":"Presentation materials for Shionogi & Co., Ltd.'s FY2026 Q2 financial results. Recorded revenue of 350.4 hundred million yen, operating income of 115.2 hundred million yen, and EBITDA of 174.6 hundred million yen. Full-year forecasts revised upward and strategy after the IntraBio acquisition explained.","jir_og_title":"Shionogi & Co., Ltd. Announces Q2 Financial Results\uff5cRevenue 350.4 hundred million yen, Operating Income 115.2 hundred million yen","jir_og_description":"Shionogi & Co., Ltd.'s FY2026 Q2 financial results: revenue 350.4 hundred million yen, operating income 115.2 hundred million yen, EBITDA 174.6 hundred million yen. Explanation of full-year forecast revisions and impact of the IntraBio acquisition.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1\\\",\\\"Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1633,3504]}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1\\\",\\\"Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[669,1152]}]}}\"}, {\"jir_chart_id\": \"ebitda_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"EBITDA Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1\\\",\\\"Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"EBITDA\\\",\\\"data\\\":[513,1746]}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Business Segment\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic Prescription Pharmaceuticals\\\",\\\"Overseas Subsidiaries\/Exports\\\",\\\"Contract Manufacturing\\\",\\\"OTC Pharmaceuticals\\\",\\\"Royalty Income\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1746,3504,144,188,3106]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Gross Margin\\\",\\\"SG&A + R&D Ratio\\\",\\\"Operating Margin\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Ratio\\\",\\\"data\\\":[? , ?, ?]}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Forecast vs. Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{\\\"headers\\\":[\\\"Item\\\",\\\"FY2026 Full-year Forecast\\\",\\\"FY2026 First Half Actuals\\\"],\\\"rows\\\":[[\\\"Revenue\\\",7000,3504],[\\\"Operating Income\\\",2200,1152]]}}\"}]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-136029","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n